These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21556565)

  • 1. Effective immune rejection of advanced metastasized cancer.
    Schirrmacher V; Beckhove P; Kruger A; Rocha M; Umansky V; Fichtner K; Hull W; Zangemeisterwittke U; Griesbach A; Jurianz K; Vonhoegen P
    Int J Oncol; 1995 Mar; 6(3):505-21. PubMed ID: 21556565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences between graft-versus-leukemia and graft-versus-host reactivity. I. Interaction of donor immune T cells with tumor and/or host cells.
    Rocha M; Umansky V; Lee KH; Hacker HJ; Benner A; Schirrmacher V
    Blood; 1997 Mar; 89(6):2189-202. PubMed ID: 9058744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft-versus-leukemia reactivity involves cluster formation between superantigen-reactive donor T lymphocytes and host macrophages.
    Müerköster S; Wachowski O; Zerban H; Schirrmacher V; Umansky V; Rocha M
    Clin Cancer Res; 1998 Dec; 4(12):3095-106. PubMed ID: 9865926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity.
    Schirrmacher V; Müerköster S; Umansky V
    Clin Cancer Res; 1998 Nov; 4(11):2635-45. PubMed ID: 9829726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-immune memory T cells from the bone marrow exert GvL without GvH reactivity in advanced metastasized cancer.
    Schirrmacher V; Beckhove P; Choi C; Griesbach A; Mahnke Y
    Int J Oncol; 2005 Oct; 27(4):1141-9. PubMed ID: 16142333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in liver glycogen and lipid metabolism during transient graft-versus-host (GvH) and graft-versus-leukemia (GvL) reactivity.
    Lee K; Hacker H; Umansky V; Schirrmacher V; Rocha M
    Int J Oncol; 1996 Oct; 9(4):635-43. PubMed ID: 21541563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons from GvL studies in animals.
    Schirrmacher V
    Cancer Immunol Immunother; 2014 Jun; 63(6):535-43. PubMed ID: 24610041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and in situ evidence for nitric oxide production driven by CD40-CD40L interactions in graft-versus-leukemia reactivity.
    Müerköster S; Laman JD; Rocha M; Umansky V; Schirrmacher V
    Clin Cancer Res; 2000 May; 6(5):1988-96. PubMed ID: 10815924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of CD4+ and CD8+ T cells to graft-versus-host disease and graft-versus-leukemia reactivity after transplantation of MHC-compatible bone marrow.
    Truitt RL; Atasoylu AA
    Bone Marrow Transplant; 1991 Jul; 8(1):51-8. PubMed ID: 1833016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of cytokines in GVL (ESb lymphoma) and GVHD after adoptive transfer of allogeneic T lymphocytes in mice.
    Gresser I; Greco G; Santini SM; Woodrow D; Mecchia M; Parlato S; Logozzi M; Venditti M; Maunoury MT; Belardelli F
    J Interferon Cytokine Res; 1998 Sep; 18(9):667-79. PubMed ID: 9781805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic separation of GvL and GvH reactivity in new recombinant-inbred tumor-resistant mouse strains.
    Schirrmacher V; Griesbach A; Gehring M; Lehr B
    Int J Oncol; 1996 Jun; 8(6):1035-43. PubMed ID: 21544461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
    Weiss L; Reich S; Slavin S
    Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
    Johnson BD; Becker EE; Truitt RL
    Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies of allogeneic tumor transplants: induced rejection of advanced tumors by immune alteration of recipients.
    Russell PS; Chase CM; Burton RC
    J Immunol; 1983 Feb; 130(2):951-7. PubMed ID: 6336775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Capacity of genetically different T lymphocytes to induce lethal graft-versus-host disease correlates with their capacity to generate suppression but not with their capacity to generate anti-F1 killer cells. A non-H-2 locus determines the inability to induce lethal graft-versus-host disease.
    Van Elven EH; Rolink AG; Veen FV; Gleichmann E
    J Exp Med; 1981 Jun; 153(6):1474-88. PubMed ID: 6454750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation.
    Korngold R; Leighton C; Manser T
    Transplantation; 1994 Aug; 58(3):278-87. PubMed ID: 7914387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.